Top

Kanazawa uiversity sets a new target for breast cancer stem-like cells

Breast cancer is cancer that develops in breast cells. Typically, the cancer forms in either the lobules or the ducts of the breast.

Anshramehdi

AnshramehdiBy Anshramehdi

Published on 13 Sep 2019 8:00 AM GMT

Kanazawa uiversity sets a new target for breast cancer stem-like cells
X
Kanazawa uiversity sets a new target for breast cancer stem-like cells
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print
  • Facebook
  • Twitter
  • Whatsapp
  • Telegram
  • Linkedin
  • Print

Lucknow: Breast cancer is cancer that develops in breast cells. Typically, the cancer forms in either the lobules or the ducts of the breast.

ALSO READ:Neetu Kapoor shares some really fun story on her Instagram handle

Lobules are the glands that produce milk, and ducts are the pathways that bring the milk from the glands to the nipple.

Drugs that disrupt the proliferation of cancer stem-like cells (CSCs) in breast tumours could help eliminate disease and prevent recurrence. A newly discovered signalling pathway now offers several promising therapeutic targets against CSCs.

ALSO READ:Not only in perfumes but rose water is also beneficial for your skin

A Kanazawa University (Japan)-led team identified a signalling molecule called semaphorin that induces the symmetric division of breast CSCs, a type of copying that makes the cancer more malignant and aggressive.

To counteract the division, the researchers experimentally knocked down the expression of other molecules that mediate semaphorin signalling in CSCs and saw that their tumour-initiating activity was markedly reduced after implantation into mice.

ALSO READ:Interpol issues Red Corner Notice against Nirav Modi’s brother

They also showed that patients with breast cancer tend to have poor outcomes if their tumour cells express high levels of a particular semaphorin-associated protein, indicating that the study findings — and the idea of targeting this pathway — could prove clinically relevant.

Anshramehdi

Anshramehdi

Next Story